A wave of insider selling at AutoZone over the past year, totaling $15 million, has drawn investor scrutiny. While the transactions occurred near current share prices, the scale of divestment compared to minimal buying prompts a closer look at the auto parts retailer's prospects.
President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank is seen as a pivotal test of its political independence, potentially aligning monetary policy more closely with White House objectives.
In a significant departure from its longstanding position, an Israeli military official has acknowledged a death toll in Gaza close to 70,000, aligning with figures long maintained by Palestinian health authorities. This admission follows over two years of war and persistent international scrutiny over casualty counts.
In its Q4 2025 letter, Greenlight Capital revealed a new position in dental distributor Henry Schein (HSIC), arguing the stock presents an opportunity for operational improvement and shareholder returns, despite recent underperformance.
Charles Schwab announces a strategic reorganization, merging its wealth advisory and banking divisions into a single unit led by long-time executive Neesha Hathi, alongside other key leadership changes.
In its Q4 2025 letter, David Einhorn's Greenlight Capital revealed a new position in Antero Resources (AR), signaling a strategic move into the natural gas sector. The hedge fund's portfolio returned 8.5% for the quarter, outpacing the S&P 500.
South Africa has declared Israel's deputy ambassador persona non grata, giving him 72 hours to depart, citing "unacceptable" diplomatic violations and insulting social media posts targeting President Ramaphosa. The move escalates tensions already frayed by South Africa's genocide case against Israel at the UN's top court.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
The AI-as-a-Service (AIaaS) market is witnessing significant growth, fueled by cloud innovation and corporate demand for scalable AI solutions. While data privacy remains a hurdle, the integration of generative AI and tailored platforms is accelerating adoption across industries.
Despite reporting earnings that edged past expectations, Houlihan Lokey's shares fell 12% post-earnings. Analysts' long-term forecasts remain largely unchanged, signaling a 'steady-as-she-goes' assessment of the investment bank's prospects.
Former Federal Reserve Governor Kevin Warsh, known for his hawkish stance but recently aligned with Trump's calls for lower rates, has been nominated by the former president to chair the Fed. The move, if confirmed, could test the institution's independence amid political pressure and an ongoing Justice Department probe.
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
A new industry analysis reveals the apparel and textiles sector is falling dangerously behind on its climate commitments, with progress too slow to meet critical international targets.
Titan Wealth Holdings has agreed to acquire Plymouth's Sound Financial Management, a move set to add approximately £600m in advised assets and bolster the group's regional presence in England's growing southwest market.
President Donald Trump has nominated Kevin Warsh, a former Federal Reserve governor and longtime critic of its recent policy, to be the next chair of the central bank, setting up a potential shift in monetary policy amid ongoing tensions over interest rates and Fed independence.
A detailed Discounted Cash Flow analysis suggests Eagle Eye Solutions Group (LON:EYE) shares are trading close to their estimated intrinsic value. We examine the assumptions behind the numbers and what investors should consider beyond the model.
Fresh Israeli military actions in central and southern Gaza have resulted in multiple casualties, testing the durability of a months-long, U.S.-brokered truce and hindering critical aid flows.
Shares of Axos Financial (AX) have surged, closing at $94.64 and delivering strong returns over multiple timeframes. This momentum has reignited the debate among investors: is the stock still undervalued against its fair value estimate of $100.50, or has the market already priced in its future growth?
New research reveals a stark preparedness gap among UK manufacturers and wholesalers for the impending EU Digital Product Passport (DPP), with nearly half unaware of the regulation that could bar non-compliant goods from the single market.
